Hereditary Cerebral Small Vessel Diseases Registry-Trial Ready Cohort
- Conditions
- Cerebral Small Vessel DiseasesHereditary
- Registration Number
- NCT06512376
- Lead Sponsor
- Beijing Tiantan Hospital
- Brief Summary
We took hereditary cerebral small vessel disease (hCSVD) patients as our main subjects, aiming to establish a platform for a comprehensive evaluation and long-term follow-up. Deeply explore the pathophysiological mechanism of hCSVD, which may render the theoretical basis for the treatment and management of hCSVD.
- Detailed Description
Cerebral Small Vessel Disease is a series of clinical, imaging, and pathological syndromes caused by a variety of risk factors affecting cerebral arterioles, arterioles, capillaries, and venules, accounting for 20% of stroke and 45% of dementia.
Although the incidence rate of hereditary small cerebral vascular disease is low, because of its early onset, high disability rate, and lack of effective treatment, it also brings a heavy burden to the patients and their families. Therefore, it is important to study the pathogenic gene, pathogenesis, clinical characteristics, and imaging manifestations of hereditary cerebrovascular disease to provide a theoretical basis for the treatment and prevention of hereditary cerebrovascular disease in the future.
This multi-center, prospective, continuous, registry study, runs from 2022 to 2027. The study is expected to recruit 100 subjects, according to the sample size design of the registry study.
We recruited patients with the hereditary cerebral small-vessel disease (hCSVD) intending to establish a platform for a comprehensive assessment and long-term follow-up by collecting genetics, imaging, and clinical symptoms of the primary disease and its relatives. With long-term follow-up of the development and prognosis of imaging and clinical symptoms combined with genetics, we will work on the correlation between genes and phenotype and deeply explore the pathophysiological mechanism of hCSVD, which may render the theoretical basis for the treatment and management of hCSVD.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 100
-
All ages, male or female
-
Carriers of the pathogenic genes mutation (mutation with unknown clinical significance/ suspected pathogenic mutation/ pathogenic mutation) of hCSVD confirmed by the gene tests, including but not limited to NOTCH3, HTPA1, CTSA, GLA, TREX1, COL4A1/2, or highly-suspected hCSVD2
-
CSVD related abnormalities on brain MRI, any 1 or more of:
- White matter hyperintensities, Fazekas score3 ≥1
- ≥1 newly-occurred lacunar infarcts
- ≥1 old lacunar infarcts
- ≥3 cerebral microbleeds
-
Informed consent signed
- Diagnosis of mental disorders according to DSM-V and unable to be compliant to the research
- Patients with life expectancy less than one year due to any advanced disease, e.g., malignant tumor
- Patients unable to return for follow-up visits due to some reasons
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The radiography features at baseline Neuroimaging markers collected by MRI
A novel pathogenic gene for hereditary cerebrovascular disease in the Chinese population at baseline Genetic testing with the blood sample
The clinical features 5 years Clinical symptoms and physical examination
The epidemiological features at baseline Any epidemiological informations
- Secondary Outcome Measures
Name Time Method Etiology and pathogenesis at baseline This study will collect etiology and pathogenesis information among participants.
Long-term changes of radiography features 5 years Neuroimaging markers collected by MRI
Trial Locations
- Locations (1)
Beijing Tiantan Hospital
🇨🇳Beijing, China